Website update in progress

Following the transformation of Polpharma Biologics (learn more), this site will focus on biosimilars development in Switzerland. In Poland, we operate now as Rezon Bio – a contract developer and manufacturer of biologics (CDMO). More at www.rezonbio.com.

Due to the demerger of Polpharma Biologics into two independent companies (detailed information can be found in the “Knowledge center” section), the website polpharmabiologics.com is currently being updated. For details on the CDMO business, please visit the Rezon Bio website

Go to Rezon Bio website

Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis

November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult […]

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides […]

Polpharma Biologics is splitting its operations into two independent companies

Polpharma Biologics is splitting its operations into two independent companies, each with a clear focus and mission.We will operate our biosimilars business out of Switzerland, under the original brand – Polpharma Biologics. We remain dedicated to developing and commercializing our pipeline of high-quality biologic medicines. We chose Switzerland, a strong biotech hub, for its proximity […]

Polpharma Biologics and MS Pharma sign licensing agreements for proposed vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars.

Amsterdam, Gdańsk – September 2nd, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading biosimilar production and distribution company in the Middle East and North Africa (MENA) region, for the commercialization of its biosimilar candidates vedolizumab […]

Polpharma Biologics and Fresenius Kabi sign licensing agreement for proposed vedolizumab biosimilar PB016

Amsterdam, Gdańsk – August 5, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and […]

Lucentis® biosimiliar Ranivisio® (ranibizumab) approved as a new treatment for debilitating retinopathies in Brazil

Amsterdam, Munich – Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the Brazilian Health Regulatory Agency (ANVISA) has approved Ranivisio®* (ranibizumab) as a biosimilar to Lucentis®** for the treatment of debilitating retinopathies in Brazil.1 Ranivisio®, developed by Bioeq (a Joint Venture between Polpharma Biologics and Formycon AG) will be exclusively […]